

IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the Application.

09/30/2007
Listing of the Claims: 20 - 21 / 1 - 8

Claim 1-19 (cancelled)

1
Claim 20 (currently amended): A method of inhibiting the binding of Tsg101 the human tumor susceptibility gene 101 protein (Tsg101) to HIV GAG the human immunodeficiency virus (HIV) GAG polyprotein (HIV GAG) comprising contacting Tsg101 with an antibody immunoreactive with the [[UEV]] ubiquitin E2 variant (UEV) domain of Tsg101, in the presence of said HIV GAG, wherein said antibody inhibits said binding.

*→ P. 72
SUPPORT*

2
Claim 21 (currently amended): The method of claim 20, wherein said binding of Tsg101 to HIV GAG occurs between the UEV domain of Tsg101 and the late domain of HIV GAG late assembly domain of HIV GAG p6.

3
Claim 22 (previously presented): The method of claim 20, wherein said antibody is selectively immunoreactive with the UEV domain of Tsg101.

4
Claim 23 (previously presented): The method of claim 20, wherein said antibody is a polyclonal antibody.

5
Claim 24 (previously presented): The method of claim 20, wherein said antibody is a monoclonal antibody.

435/5

C 12 Q 1170

424/208.1

A 61 K 39/21

Page 2 of 10

103 - 107

1111100

6
Claim **25** (previously presented): The method of claim **20**, wherein said antibody is an antibody fragment.

7
Claim **26** (previously presented): The method of claim **20**, wherein said antibody is a single chain antibody.

8
Claim **27** (previously presented): The method of claim **20**, wherein said antibody is a humanized antibody.

IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the Application.

Listing of the Claims:

Claim 1-19 (cancelled)

Claim 20 (currently amended): A method of inhibiting the binding of Tsg101-the human tumor susceptibility gene 101 protein (Tsg101) to HIV-GAG the human immunodeficiency virus (HIV) GAG polyprotein (HIV GAG) comprising contacting Tsg101 with an antibody immunoreactive with the [[UEV]] ubiquitin E2 variant (UEV) domain of Tsg101, in the presence of said HIV GAG, wherein said antibody inhibits said binding.

Claim 21 (currently amended): The method of claim 20, wherein said binding of Tsg101 to HIV GAG occurs between the UEV domain of Tsg101 and the ~~late domain of HIV GAG~~ late assembly domain of HIV GAG p6.

Claim 22 (previously presented): The method of claim 20, wherein said antibody is selectively immunoreactive with the UEV domain of Tsg101.

Claim 23 (previously presented): The method of claim 20, wherein said antibody is a polyclonal antibody.

Claim 24 (previously presented): The method of claim 20, wherein said antibody is a monoclonal antibody.

Appl. No. 10/663,407
Amdt. dated May 21, 2007
Reply to Office Action of February 26, 2007

Claim 25 (previously presented): The method of claim 20, wherein said antibody is an antibody fragment.

Claim 26 (previously presented): The method of claim 20, wherein said antibody is a single chain antibody.

Claim 27 (previously presented): The method of claim 20, wherein said antibody is a humanized antibody.